2Aoki Y,Tomita M,Sato T,etal.Neoadjuvant chemotherapy for patients younger than 50 years with high-risk squamouscell carcinoma of the cervix.Gynecol Oncol,2001,83:263-267.
3Benedetti-Panici P,Greggi S,Colombo A,et al.Neoadjuvant chemotherapy and radicalsurgery versus exclusive radiotherapy in locally advanced squamous cell cervicalcancer:results from the Italian multicenter randomized study.J Clin Oncol,2002,20:179-188.
4Hwang YY,Moon H,Cho SH,et al.Ten-year survival of patients with locally advanced,stageⅠb-Ⅱb cervical cancer after neoadjuvant chemotherapy and radical hysterectomy.GynecolOncol,2001,82:88-93.
5Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysisCollaboration.Neoadjuvant chemotherapy for locally advanced cervical cancer:a systematicreview and meta-analysis of individual patient data from 21 randomised trials.Eur JCancer,2003,39:2470-2486.
6Tabata T,Takeshima N,Nishida H,et al.A randomized study of primarybleomycin,vincristine,mitomycin and cisplatin (BOMP) chemotherapy followed by radiotherapyversus radiotherapy alone in stage IIIB and IVA squamous cell carcinoma of thecervix.Anticancer Res,2003,23:2885-2890.
7Duenas-Gonzalez A,Rivera L,Mota A,et al.The advantages of concurrent chemoradiationafter neoadjuvant chemotherapy for locally advanced cervical carcinoma.Arch MedRes,2002,33:201-202.
8Manusirivithaya S,Chareoniam V,Pantusart A,et al.Comparative study of bulky stage IBand IA cervical cancer patients treated by radical hysterectomy with and withoutneoadjuvant chemotherapy:long-term follow-up.J Med Assoc Thai,2001,84:1550-1557.
5Bosch FX, De sanjose S. Chapterl : Human papillomaviurs and cervical cancer-burden and assessment of causality [ J ]. J Natl cancer lnst Monogr.2003,31:3-13.
6Munoz N, Bosch FX, De Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical [ J ]. N Engl J Med ,2003,348:518-527.
